Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3 studies found for:    23830355 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Unknown 
Has Results
A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1349572;   Drug: Raltegravir;   Drug: GSK1349572 Placebo;   Drug: Raltegravir Placebo
2 Recruiting A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia
Condition: HIV-1 Infection
Intervention: Drug: atazanavir 300 mg + ritonavir 100 mg + dolutegravir 50 mg
3 Recruiting Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection
Conditions: HIV;   Acute HIV Infection
Intervention: Drug: DTG/3TC/ABC FDC

Study has passed its completion date and status has not been verified in more than two years.